Metastases in the central nervous system (CNS) are the most common neurooncological tumors, most often originating from lung cancer, breast cancer or melanoma. In recent years, the incidence of CNS metastasis is rising, probably due to improved treatment options for primary solid tumors outside the CNS. The molecular mechanisms leading to CNS metastasis are not yet fully understood, and novel effective therapeutic options are urgently needed.
High-throughput technologies (proteomics, genomics, transcriptomics) and the bioinformatical analysis enables us to close this gap in knowledge. The development of personalised, integrative data sets of each individual patient - comprising information from these diverse sources - makes it possible to find new relevant, oncogenic signaling pathways and identify potential therapeutic targets. Combined therapeutic strategies that target oncogenic signals and activate the immune system could be very efficient strategy.